80 related articles for article (PubMed ID: 21059092)
1. The effects of rosiglitazone on atherosclerotic progression in patients with Type 2 diabetes at high cardiovascular risk.
Yee MS; Pavitt DV; Dhanjil S; Godsland IF; Richmond W; Johnston DG
Diabet Med; 2010 Dec; 27(12):1392-400. PubMed ID: 21059092
[TBL] [Abstract][Full Text] [Related]
2. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Hedblad B; Zambanini A; Nilsson P; Janzon L; Berglund G
J Intern Med; 2007 Mar; 261(3):293-305. PubMed ID: 17305652
[TBL] [Abstract][Full Text] [Related]
3. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.
Sidhu JS; Kaposzta Z; Markus HS; Kaski JC
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):930-4. PubMed ID: 15001452
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
6. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; Van Es GA; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ;
Am Heart J; 2008 Dec; 156(6):1074-9. PubMed ID: 19033001
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance.
Varghese A; Yee MS; Chan CF; Crowe LA; Keenan NG; Johnston DG; Pennell DJ
J Cardiovasc Magn Reson; 2009 Jul; 11(1):24. PubMed ID: 19635160
[TBL] [Abstract][Full Text] [Related]
9. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.
Davidson M; Meyer PM; Haffner S; Feinstein S; D'Agostino R; Kondos GT; Perez A; Chen Z; Mazzone T
Circulation; 2008 Apr; 117(16):2123-30. PubMed ID: 18413496
[TBL] [Abstract][Full Text] [Related]
10. Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.
Han SJ; Hur KY; Kim YS; Kang ES; Kim SI; Kim MS; Kwak JY; Kim DJ; Choi SH; Cha BS; Lee HC
Nephrol Dial Transplant; 2010 Mar; 25(3):976-84. PubMed ID: 19875376
[TBL] [Abstract][Full Text] [Related]
11. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
Mazzone T; Meyer PM; Feinstein SB; Davidson MH; Kondos GT; D'Agostino RB; Perez A; Provost JC; Haffner SM
JAMA; 2006 Dec; 296(21):2572-81. PubMed ID: 17101640
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
14. A comparison of ultrasound measurements to assess carotid atherosclerosis development in subjects with and without type 2 diabetes.
Pollex RL; Spence JD; House AA; Fenster A; Hanley AJ; Zinman B; Harris SB; Hegele RA
Cardiovasc Ultrasound; 2005 Jun; 3():15. PubMed ID: 15958169
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study.
Langenfeld MR; Forst T; Hohberg C; Kann P; Lübben G; Konrad T; Füllert SD; Sachara C; Pfützner A
Circulation; 2005 May; 111(19):2525-31. PubMed ID: 15883215
[TBL] [Abstract][Full Text] [Related]
16. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
19. Effects of comprehensive intensive therapies on the change of intima-media thickness of carotid arteries in type 2 diabetic patients: A report of 4-year follow-up with a literature review.
Cheng LJ; Xu ZR; Zhang Q; Wang ZD; Wu FW; Yang WX
Diab Vasc Dis Res; 2016 Jan; 13(1):31-40. PubMed ID: 26499916
[TBL] [Abstract][Full Text] [Related]
20. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment.
Marfella R; D'Amico M; Esposito K; Baldi A; Di Filippo C; Siniscalchi M; Sasso FC; Portoghese M; Cirillo F; Cacciapuoti F; Carbonara O; Crescenzi B; Baldi F; Ceriello A; Nicoletti GF; D'Andrea F; Verza M; Coppola L; Rossi F; Giugliano D
Diabetes; 2006 Mar; 55(3):622-32. PubMed ID: 16505224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
